1. Development of an intracellularly acting inhibitory peptide selective for PKN
- Author
-
Yoshitaka Ono, Lewis C. Cantley, Katsuko Ueki, Kentaro Takayama, Kazuhiro Shiga, Shiroh Futaki, Hideyuki Mukai, and Jessica E. Hutti
- Subjects
chemistry.chemical_classification ,Cell Membrane Permeability ,Kinase ,Autophosphorylation ,Peptide ,Cell Biology ,Biology ,Biochemistry ,Peptide Fragments ,Article ,Substrate Specificity ,Serine ,chemistry ,Peptide Library ,Humans ,Protein Isoforms ,Phosphorylation ,Kinase activity ,Peptide library ,Molecular Biology ,Protein Kinase C ,Protein kinase C ,HeLa Cells - Abstract
PKNs form a subfamily of the AGC serine/threonine protein kinases, and have a catalytic domain homologous with that of PKC (protein kinase C) in the C-terminal region and three characteristic ACC (antiparallel coiled-coil) domain repeats in the N-terminal region. The preferred peptide phosphorylation motif for PKNs determined by a combinatorial peptide library method was highly similar to that of PKCs within a 10-amino-acid stretch. Previously reported PKN inhibitory compounds also inhibit PKCs to a similar extent, and no PKN selective inhibitors have been commercially available. We have identified a 15-amino-acid peptide inhibitor of PKNs based on amino acids 485–499 of the C-terminal region of the C2-like domain of PKN1. This peptide, designated as PRL, selectively inhibits the kinase activity of all isoforms of PKN (Ki=0.7 μM) towards a peptide substrate, as well as autophosphorylation activity of PKN in vitro, in contrast with PKC. Reversible conjugation by a disulfide bond of a carrier peptide bearing a penetration accelerating sequence to PRL, facilitated the cellular uptake of this peptide and significantly inhibited phosphorylation of tau by PKN1 at the PKN1-specific phosphorylation site in vivo. This peptide may serve as a valuable tool for investigating PKN activation and PKN-mediated responses.
- Published
- 2009
- Full Text
- View/download PDF